591 related articles for article (PubMed ID: 19306900)
1. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
[TBL] [Abstract][Full Text] [Related]
2. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
5. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
7. Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.
Schuster L; Seifert O; Vollmer S; Kontermann RE; Schlosshauer B; Hartmann H
Mol Pharm; 2015 Sep; 12(9):3146-57. PubMed ID: 26181293
[TBL] [Abstract][Full Text] [Related]
8. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.
Gerspach J; Müller D; Münkel S; Selchow O; Nemeth J; Noack M; Petrul H; Menrad A; Wajant H; Pfizenmaier K
Cell Death Differ; 2006 Feb; 13(2):273-84. PubMed ID: 16052236
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
10. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
Baum P; Müller D; Rüger R; Kontermann RE
J Drug Target; 2007 Jul; 15(6):399-406. PubMed ID: 17613658
[TBL] [Abstract][Full Text] [Related]
11. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
[TBL] [Abstract][Full Text] [Related]
12. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
[TBL] [Abstract][Full Text] [Related]
13. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
14. Polymeric nanoparticles for drug delivery.
Chan JM; Valencia PM; Zhang L; Langer R; Farokhzad OC
Methods Mol Biol; 2010; 624():163-75. PubMed ID: 20217595
[TBL] [Abstract][Full Text] [Related]
15. Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies.
Debs RJ; Düzgüneş N; Brunette EN; Fendly B; Patton J; Philip R
J Immunol; 1989 Aug; 143(4):1192-7. PubMed ID: 2787358
[TBL] [Abstract][Full Text] [Related]
16. A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery.
Xu Y; Jin X; Ping Q; Cheng J; Sun M; Cao F; You W; Yuan D
J Control Release; 2010 Sep; 146(3):299-308. PubMed ID: 20580913
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
18. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.
Hayes ME; Drummond DC; Hong K; Zheng WW; Khorosheva VA; Cohen JA; C O N; Park JW; Marks JD; Benz CC; Kirpotin DB
Mol Pharm; 2006; 3(6):726-36. PubMed ID: 17140260
[TBL] [Abstract][Full Text] [Related]
19. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes.
Barauskas J; Cervin C; Jankunec M; Spandyreva M; Ribokaite K; Tiberg F; Johnsson M
Int J Pharm; 2010 May; 391(1-2):284-91. PubMed ID: 20214966
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
Kircheis R; Ostermann E; Wolschek MF; Lichtenberger C; Magin-Lachmann C; Wightman L; Kursa M; Wagner E
Cancer Gene Ther; 2002 Aug; 9(8):673-80. PubMed ID: 12136428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
